Latest From LimFlow SA
R&D Roundup, November 2019: LimFlow Starts Pivotal Trial Of Peripheral Shunt; Conservative Coronary Treatment Matches Intervention In Trial
An overview of November’s 10 most-read Medtech Insight articles on topics related to research and development of new medical technology.
The results from the PROMISE I feasibility study give LimFlow confidence that the PROMISE II pivotal trial will prove that the LimFlow percutaneous deep vein arterialization system is a safe and effective alternative to amputation for patients with critical limb ischemia.
Diagnostic Imaging Equipment & Supplies
Surgical Equipment & Devices
- Minimally or Less Invasive
- Diagnostic Imaging Equipment & Supplies
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- LimFlow SA
- Senior Management
Dan Rose, CEO
Tim Lenihan, CTO
Paul Limmer, VP, Fin. & Admin.
- Contact Info
Phone: 638 747 190
95bis Boulevard Pereire
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.